The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Omcazio cabozantinib laurylsulfate New formulation or manufacturer | Handa Oncol | 🇺🇸 US 2026-09-03 | Order → | |
| Zanvastro zilganersen sodium New molecular entityPriority review | Ionis Pharms Inc | 🇺🇸 US 2026-09-03 | Order → | |
| Denosumab Ascend denosumab BiosimilarAdditional monitoring | Ascend GmbH | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | 🇪🇺 EU 2026-08-28 | Order → |
| Mimrylo rusfertide acetate New molecular entityPriority review | Takeda Pharms Am | 🇺🇸 US 2026-08-28 | Order → | |
| Bixlenvo bictegravir sodium, lenacapavir sodium New combinationPriority review | Gilead Sciences Inc | 🇺🇸 US 2026-08-27 | Order → | |
| Bixlenvo Sunlenca Starter Pack (Copackaged) bictegravir sodium, lenacapavir sodium, lenacapavir sodium New combination | Gilead Sciences Inc | 🇺🇸 US 2026-08-27 | Order → | |
| Lisraya brepocitinib tosylate New molecular entityPriority review | Priovant Therap | 🇺🇸 US 2026-08-27 | Order → | |
| Rasonque daraxonrasib New molecular entityPriority review | Revolution Medicines | 🇺🇸 US 2026-08-26 | Order → | |
| Vobrig leuprolide acetate New formulation or manufacturer | Sun Pharm | 🇺🇸 US 2026-08-26 | Order → | |
| Aujemflu Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture) | Seqirus Netherlands B.V. | Influenza, Human | 🇪🇺 EU 2026-08-20 | Order → |
| Daybu trofinetide OrphanAdditional monitoring | Acadia Pharmaceuticals B.V. | Rett Syndrome | 🇪🇺 EU 2026-08-20 | Order → |
| Hopledo levodopa;carbidopa | Zambon SpA | Parkinson Disease | 🇪🇺 EU 2026-08-20 | Order → |
| Pasatru garetosmab-grts New biologicPriority review | Regeneron Pharmaceuticals, Inc | 🇺🇸 US 2026-08-19 | Order → | |
| Sodium Bicarbonate sodium bicarbonate New formulation or manufacturer | Baxter Hlthcare Corp | 🇺🇸 US 2026-08-14 | Order → | |
| Tauklarify florquinitau f-18 New molecular entity | Cerveau Lantheus | 🇺🇸 US 2026-08-13 | Order → | |
| Zenbexus iberdomide hydrochloride New molecular entityPriority review | Bristol Myers Squibb | 🇺🇸 US 2026-08-13 | Order → | |
| Nitrous Oxide, Usp nitrous oxide | Linde Gas Equip | 🇺🇸 US 2026-08-09 | Order → | |
| Orzeyful oveporexton New molecular entityPriority review | Takeda Pharms Usa | 🇺🇸 US 2026-08-05 | Order → | |
| Zimrixby rituximab-cdxx Biosimilar | Dr Reddys Labs Sa | 🇺🇸 US 2026-07-31 | Order → | |
| Glycophos sodium glycerophosphate New active ingredient | Fresenius Kabi Usa | 🇺🇸 US 2026-07-29 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.